iCAD (ICAD) Hits New 12-Month Low at $2.65

iCAD Inc (NASDAQ:ICAD) shares reached a new 52-week low during trading on Monday . The company traded as low as $2.65 and last traded at $2.67, with a volume of 1600 shares changing hands. The stock had previously closed at $2.89.

The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.39 and a current ratio of 1.58. The stock has a market cap of $48.73 million, a P/E ratio of -4.61 and a beta of 0.80.

iCAD (NASDAQ:ICAD) last posted its earnings results on Tuesday, August 14th. The technology company reported ($0.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.06. iCAD had a negative net margin of 56.53% and a negative return on equity of 62.50%. The company had revenue of $6.16 million for the quarter, compared to analysts’ expectations of $6.84 million. On average, research analysts predict that iCAD Inc will post -0.41 earnings per share for the current fiscal year.

WARNING: This news story was published by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.wkrb13.com/2018/11/07/icad-icad-hits-new-12-month-low-at-2-65.html.

iCAD Company Profile (NASDAQ:ICAD)

iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.

See Also: Exchange-Traded Funds (ETFs)

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply